



J. B. Chemicals & Pharmaceuticals Limited

AUDITED FINANCIAL RESULTS FOR THE YEAR ENDED 31ST MARCH 2011

Sr. No.	PARTICULARS	Rs. in lacs					
		QUARTER ENDED		YEAR ENDED		CONSOLIDATED FINANCIAL RESULTS YEAR ENDED	
		31/03/2011	31/03/2010	31/03/2011 (Audited)	31/03/2010 (Audited)	31/03/2011 (Audited)	31/03/2010 (Audited)
1	a) Net Sales (Net of excise)	17,889.06	16,571.64	78,757.94	67,006.45	87,168.09	74,097.47
	b) Other Operating Income	497.09	437.09	1,912.61	1,532.87	1,912.61	1,590.92
	Total Income	18,386.15	17,008.73	80,670.55	68,539.32	89,080.70	75,688.39
2	Expenditure						
	a) (Increase)/Decrease in Stock in Trade & WIP	(964.89)	(268.61)	(1,286.13)	(321.94)	(1,286.13)	(321.94)
	b) Consumption of Raw Materials	5,119.94	3,685.92	20,900.33	16,126.49	20,900.33	16,126.49
	c) Purchase of Traded Goods	1,151.47	1,399.99	4,691.52	4,410.23	7,782.99	7,753.01
	d) Employees Cost	2,819.36	2,766.96	11,642.70	9,846.93	12,493.30	10,521.40
	e) Depreciation	567.78	526.25	2,265.08	2,122.25	2,278.78	2,156.86
	f) Sales Promotion & Publicity	2,973.85	2,335.86	10,527.89	8,752.12	10,749.80	8,963.00
	g) Exchange Fluctuation Suffered (Gain)/Loss	(200.10)	236.40	16.75	1,516.20	434.35	486.30
	h) Other Expenditure	4,527.09	3,885.04	17,234.34	14,541.38	19,388.38	16,196.88
	Total	15,994.50	14,567.81	65,992.48	56,993.66	72,741.80	61,882.00
3	Profit from operations before Other Income & Interest (1-2)	2,391.65	2,440.92	14,678.07	11,545.66	16,338.90	13,806.39
4	Other Income	208.78	167.52	586.79	192.47	614.63	200.61
5	Profit before Interest (3+4)	2,600.43	2,608.44	15,264.86	11,738.13	16,953.53	14,007.00
6	Interest	190.29	167.49	737.30	894.51	737.30	906.80
7	Profit after Interest but before Exchange Fluctuation Gain / (Loss) (5-6)	2,410.14	2,440.95	14,527.56	10,843.62	16,216.23	13,100.20
8	Exchange Fluctuation Gain / (Loss)	(617.02)	679.32	(422.22)	1,250.80	317.76	1,707.07
9	Profit from Ordinary Activities Before Tax (7-8)	1,793.12	3,120.27	14,105.34	12,094.42	16,533.99	14,807.27
10	Tax Expenses :						
	Current Tax	348.00	466.01	2,810.00	2,067.00	3,266.09	2,836.71
	MAT Credit Entitlement	(140.00)	-	(550.00)	-	(550.00)	-
	Deferred Tax	99.98	63.25	19.63	79.48	(17.09)	247.09
	Short/(Excess) Provision for Taxation for prior year	8.59	(106.65)	6.25	(151.79)	(97.38)	(151.79)
11	Profit from Ordinary Activities After Tax (9-10)	1,476.55	2,697.66	11,819.46	10,099.73	13,932.37	11,875.26
	Net Profit attributable to Parent	-	-	-	-	13,932.37	11,875.26
12	Paid-up Equity Share Capital (Face Value Rs. 2/- per share)	1,690.34	1,686.53	1,690.34	1,686.53	1,690.34	1,686.53
13	Reserves (excluding Revaluation Reserve) as per balance sheet of previous accounting year	-	-	69,637.93	59,650.61	66,682.92	54,703.91
14	Earnings Per Share (EPS)						
	a) Basic (Not annualised)	1.75	3.20	14.00	11.98	16.50	14.08
	b) Diluted (Not annualised)	1.74	3.20	13.96	11.98	16.46	14.08
15	Public Shareholding						
	No. of shares	37,663,735	37,470,610	37,663,735	37,470,610	-	-
	% of shareholding	44.56	44.44	44.56	44.44	-	-
16	Promoters and Promoter Group Shareholding						
	a) Pledged/Encumbered						
	Number of shares	-	-	-	-	-	-
	Percentage of shares (as a % of the shareholding of promoter and promoter group)	-	-	-	-	-	-
	Percentage of shares (as a % of the total share capital of the company)	-	-	-	-	-	-
	b) Non-encumbered						
	Number of shares	46,853,090	46,855,740	46,853,090	46,855,740	-	-
	Percentage of shares (as a % of the shareholding of promoter and promoter group)	100	100	100	100	-	-
	Percentage of shares (as a % of the total share capital of the company)	55.44	55.56	55.44	55.56	-	-

NOTES :

1. The above audited financial results have been reviewed by the Audit Committee and approved by the Board of Directors at in meeting held on May 23, 2011.
2. The Board of Directors has recommended a dividend of Rs.2 (100%) per equity share of Rs.2/-. This together with dividend distribution tax will absorb Rs.1,966.23 lacs.
3. The board of directors, at its meeting held on May 23, 2011, has approved entering into definitive agreement for sale of the company's Russia/CIS over the counter (OTC) products business to Cilag GmbH International ("Cilag"), a wholly owned subsidiary of Johnson & Johnson, for consideration of Rs.9385.10 Million. The board has also approved the transfer of worldwide rights for 3 trademarks viz. Doktor Mom, Rinza and Fitovit to Cilag for additional consideration of Rs. 60.67 Million. Cilag's affiliate, Johnson & Johnson LLC, has also entered into a contract with the company's wholly owned subsidiary situated in Russia for purchase of its OTC inventory and receivables for consideration of US\$ 47 Million.
4. There were no outstanding complaints from investors at the beginning of the quarter. The Company received 6 complaints from the investors during the quarter, which have been disposed of during the quarter.
5. The Company is engaged in a single segment of activity namely, "Pharmaceuticals".
6. During the quarter, the company allotted 20,775 equity shares against exercise of stock options.
7. The statement of assets and liabilities as of March 31, 2011 is as under:

Particulars	Standalone		Consolidated	
	Audited		Audited	
	31-Mar-11	31-Mar-10	31-Mar-11	31-Mar-10
Shareholders' Funds:				
(a) Capital	1,690.34	1,686.53	1,690.34	1,686.53
(b) Reserves and Surplus	69,637.93	59,650.61	67,463.91	55,125.22
Loan Funds	16,856.32	13,622.45	16,905.93	13,677.96
Deferred Tax Liability	1,443.62	1,423.99	1,626.91	1,585.45
Total	89,628.21	76,383.58	87,687.09	72,075.16
FIXED ASSETS	22,894.44	21,807.85	26,214.38	24,685.60
INVESTMENTS	12,328.84	6,246.43	8,498.27	2,427.29
CURRENT ASSETS, LOANS AND ADVANCES				
(a) Inventories	8,178.22	5,640.84	11,167.02	8,347.15
(b) Sundry Debtors	38,545.42	40,727.14	34,558.25	34,482.38
(c) Cash and Bank balances	12,291.77	7,056.63	12,688.57	7,786.19
(d) Loans and advances	6,488.05	5,550.89	6,811.48	5,968.19
Less:Current Liabilities and Provisions				
(a) Liabilities	7,688.67	7,318.30	8,825.97	8,280.99
(b) Provisions	3,409.86	3,327.90	3,424.90	3,340.65
Total	89,628.21	76,383.58	87,687.09	72,075.16

8. Previous quarter's / period's figures have been regrouped / re-stated, wherever necessary

For J.B. CHEMICALS & PHARMACEUTICALS LTD.

Place : Mumbai
Date : May 23, 2011

J.B.MODY
CHAIRMAN & MANAGING DIRECTOR